Overall, in both studies, patients who received Viraferon plus ribavirin, were less likely to respond than patients who received pegylated t
Üldiselt oli mõlemas uuringus ravivastuse saavutamine vähem tõenäoline neil patsientidel, kes said Viraferon’ d pluss ribaviriini võrreldes patsientidega, kes said pegüleeritud interferooni alfa- 2b koos ribaviriiniga.